DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
NVCR logo

NovoCure Limited Stock Price

NasdaqGS:NVCR Community·US$1.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 30 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

NVCR Share Price Performance

US$16.22
3.50 (27.52%)
​
US$26.07
Fair Value
US$16.22
3.50 (27.52%)
37.8% undervalued intrinsic discount
US$26.07
Fair Value
Price US$16.22
AnalystConsensusTarget US$26.07
AnalystLowTarget US$17.00
AnalystHighTarget US$48.93
Fri, 3 Apr 26
Fair ValueUS$26.07
Share Pricen/a

NVCR Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$26.07 37.8% undervalued intrinsic discount

NVCR: Regulatory Wins And Clinical Milestones Will Drive Oncology Expansion

0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$17 4.6% undervalued intrinsic discount

Regulatory Delays And Setbacks Will Restrict Adoption Yet Allow Recovery

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$48.93 66.9% undervalued intrinsic discount

TTFields Will Lead Oncological Advancements For Aging Populations

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
NVCR logo
NovoCure
66.9% undervalued intrinsic discount

TTFields Will Lead Oncological Advancements For Aging Populations

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 28 Jul
Read Narrative
NVCR logo
NovoCure
4.6% undervalued intrinsic discount

Regulatory Delays And Setbacks Will Restrict Adoption Yet Allow Recovery

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 17 May
Read Narrative
NVCR logo
NovoCure
37.8% undervalued intrinsic discount

NVCR: Regulatory Wins And Clinical Milestones Will Drive Oncology Expansion

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 3 Apr
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
NVCR logo

NVCR: Pancreatic Cancer Approval Will Drive Future Tumor Treating Fields Expansion

Fair Value: US$48.93 66.9% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
NVCR logo

NVCR: Mixed TTFields Progress And Guidance Will Shape Shares In 2026

Fair Value: US$17 4.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
NVCR logo

NVCR: Recovering Procedure Trends And 2026 Tools Play Will Drive Upside

Fair Value: US$26.07 37.8% undervalued intrinsic discount
11 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with excellent balance sheet.

1 Risk
3 Rewards
View Full Analysis

NovoCure Limited Key Details

US$699.2m

Revenue

US$165.2m

Cost of Revenue

US$534.0m

Gross Profit

US$682.5m

Other Expenses

-US$148.6m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-1.28
76.37%
-21.25%
57.9%
View Full Analysis

About NVCR

Founded
2000
Employees
1605
CEO
Frank Leonard
WebsiteView website
www.novocure.com

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Recent NVCR News & Updates

User avatar
Narrative Update • Jul 28

NVCR: Pancreatic Cancer Approval Will Drive Future Tumor Treating Fields Expansion

Analysts have raised the implied fair value estimate for NovoCure to about $48.93 from $42.97, citing higher Street price targets supported by recent record revenue, increased company guidance, and updated assumptions for revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent Street research on NovoCure highlights a mix of optimism and caution, with several bullish analysts reacting to the record revenue quarter, raised guidance, and updated revenue assumptions.

Recent updates

No updates

NovoCure Limited Competitors

ALGN logo

Align Technology

Symbol: NasdaqGS:ALGN
Market cap: US$10.7b
MOH logo

Molina Healthcare

Symbol: NYSE:MOH
Market cap: US$10.6b
UHS logo

Universal Health Services

Symbol: NYSE:UHS
Market cap: US$10.3b
COO logo

Cooper Companies

Symbol: NasdaqGS:COO
Market cap: US$10.3b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide